Clinical features and recurrence of Corynebacterium kroppenstedtii infection in patients with mastitis
0301 basic medicine
Corynebacterium kroppenstedtii
Cefuroxime
Suppuration
Corynebacterium Infections
Research
Clinical features
Gynecology and obstetrics
Corynebacterium
Triamcinolone Acetonide
Anti-Bacterial Agents
3. Good health
Treatment
03 medical and health sciences
Granulomatous lobular mastitis
Antibiotics
RG1-991
Humans
Female
Granulomatous Mastitis
Public aspects of medicine
RA1-1270
DOI:
10.1186/s12905-022-01859-y
Publication Date:
2022-07-06T08:04:05Z
AUTHORS (8)
ABSTRACT
Abstract
Background
Few studies have investigated the differences in clinical features of patients with mastitis following Corynebacterium kroppenstedtii infection, and most focused on the bacterial antimicrobial susceptibility, detection methods and therapy.
Methodology
There were 133 patients with mastitis infected by C. kroppenstedtii between August 2016 and September 2019. C. kroppenstedtii was identified using mass spectrometry. The demographics, clinical diagnosis, laboratory test results of different types of mastitis combined with bacillus infection, and the effects of different treatments in reducing recurrence were compared.
Results
The incidence of pus following C. kroppenstedtii infection was higher in patients with non-granulomatous lobular mastitis (NGLM; 56.6%) than in those with granulomatous lobular mastitis (GLM; 33.3%; χ2 = 7.072, p = 0.008). While C-reactive protein (CRP) was higher in the GLM group (12.50 mg/L) than in the NGLM group (6.05 mg/L; Z = − 2.187, p = 0.029). Treatment with local lavage (triamcinolone acetonide) and antibiotics (cefuroxime) showed a recurrent rate of 25.9% in C. kroppenstedtii infection.
Conclusion
Increased pus, large masses, and an elevated CRP level may occur in patients with mastitis infected by C.kroppenstedtii. These clinical features may guide the determination of the bacterial infection in patients with mastitis. Combining an antibiotic with a triamcinolone acetonide lavage, preferably cefuroxime, may reduce the recurrence.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (25)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....